Abstract: Leukocytes are professionals in recognizing and removing pathogenic or unwanted material. They are present in virtually all tissues, and highly motile to enter or leave specific sites throughout the body. Less than a decade ago, physical plasmas entered the field of medicine to deliver their delicate mix of reactive species and other physical agents for mainly dermatological or oncological therapy. Plasma treatment thus affects leukocytes via direct or indirect means: immune cells are either present in tissues during treatment, or infiltrate or exfiltrate plasma-treated areas. The immune system is crucial for human health and resolution of many types of diseases. It is therefore vital to study the response of leukocytes after plasma treatment in vitro and in vivo. This review gathers together the major themes in the plasma treatment of innate and adaptive immune cells, and puts these into the context of wound healing and oncology, the two major topics in plasma medicine.
Introduction: clinical applications of physical plasma
Cold physical plasma is a partially ionized gas operated at body temperature that generates electrical fields, light of various wavelengths and reactive species (Laroussi et al., 2017) . The latter are of major relevance in mediating plasma effects in biological targets (Lu et al., 2016) . This links many findings in the field of plasma medicine to redox biology (Graves, 2012) . However, plasmas are unique in delivering a mixture of reactive species directly from the gas phase (over liquids) to cells and tissues. The type, amount and spatio-temporal resolution of these species depend on the source type and setting (Winter et al., 2015) , and can include many well-known reactive species such as nitric oxide (NO), superoxide, hydroxyl radical, atomic oxygen, singlet oxygen or ozone (SchmidtBleker et al., 2014) . Also less known reactive intermediates can be generated, including nitrogen or argon metastables if noble gases are used as the feed gas (Bekeschus et al., 2015) . Most importantly, the technical parameters allow to 'tune' the reactive species output to some extent (Cheng et al., 2014) , allowing in principle tailoring of applications or disease-specific plasma treatment. Plasmamediated, multiplexed redox interventions are inherently different from other physical technologies in medicine. Focused energy of lasers are often used for depigmentation (Metelmann et al., 2011) and cutting in surgery (Hüt-temann et al., 2012) , photodynamic therapy generates intracellular singlet oxygen that targets the endoplasmic reticulum (Garg et al., 2011) , UV radiation leads to in situ radical formation (Wolfle et al., 2011) , and ionizing radiation induces not only DNA double-strand but also breaks hydroxyl radical formation in cells (Lomax et al., 2013) . With all these applications, reactive species formation appears secondary and intracellularly after treatment. By contrast, using physical plasmas, exogenous (extracellular) reactive species are the primary agens movens.
As cold physical plasmas are generated in the ambient air, medical applications focus on easy-to-reach target tissues that allow for repetitive treatments. This is especially given in dermatology and dermato-oncology. Plasma treatment supports the healing of non-healing ulcers across different plasma devices and clinics (Brehmer et al., 2015; Ulrich et al., 2015; Chuangsuwanich et al., 2016) . The antimicrobial efficacy of plasma in chronic wounds likely plays a part in these responses (Isbary et al., 2010 (Isbary et al., , 2012 Chuangsuwanich et al., 2016) . Other applications in dermatology that have been partially explored are for instance burn wounds (Betancourt-Angeles et al., 2017) , herpes zoster (Isbary et al., 2014) , psoriasis (Klebes et al., 2014) , cutaneous microcirculation (Kisch et al., 2016) , acute surgical wounds (Hartwig et al., 2017) , healing of skin graft donor sites (Heinlin et al., 2013) and decontamination of superficial driveline infections (Hilker et al., 2017 ). An upcoming and extremely promising field is the treatment of actinic keratosis (Daeschlein et al., 2017; Friedman et al., 2017; Wirtz et al., 2018) , a precancerous condition with millions of new cases per year in the Western world (Salasche, 2000) . This closely connects to dermato-oncology (Weishaupt and Emmert, 2018) . Targeting malignant melanoma is one upcoming horizon with physical plasma treatment (Pasqual-Melo et al., 2018) . In addition, originally patients suffering from end stage head and neck cancer benefited from plasma therapy (Metelmann et al., 2018) . A decrease of myeloid cells in the plasma group suggested a role of immune cells in the response.
The immune system is tightly entangled in controlling health and disease. In oncology, immune therapies such as checkpoint inhibition are major breakthroughs in the field (Gotwals et al., 2017) . The principle is to unleash the endogenous power of immunity that often is suppressed by tumor cells to eradicate cancers (Sharpe, 2017) . Because this is a universal approach utilizing tumor-specific T cells unique in each patient, it works in many different types of malignancies (Tran et al., 2017) . At the same time, it relieves the immunosuppressive environment that often is established by for instance monocyte-derived macrophages (Kostine et al., 2018) . This microenvironment is tumor supportive by the supply of factors that are in part similar to wound healing processes (Schafer and Werner, 2008) .
Immune cells are of major importance in wound healing (Park and Barbul, 2004) . They magnificently shape the microenvironment required to initialize each step of the healing cascade. This is done via timed infiltration and exfiltration rates of different immune cell subtypes and their release of cytokines and chemokines that signal required responses to fibroblasts and keratinocytes (Galkowska et al., 2006; Behm et al., 2012; Barrientos et al., 2014) . After injury, neutrophils dominate the wound bed to eradicate invading microorganisms, followed by monocytes/macrophages that release signals to decrease neutrophil influx and increase lymphocyte infiltration in the course of healing (DiPietro, 1995; Agaiby and Dyson, 1999; Rodero and Khosrotehrani, 2010) . Other dermatological diseases also involve immune cells. For example, burn wounds show excessive tissue necrosis and uncontrolled microbial colonization (Park et al., 2017) , herpes infections require appropriate cytotoxic T cell responses (Shin, 2018) , and psoriasis is an autoimmune disease (Kim and Krueger, 2017) . Hence, it is important to study leukocytes and their subsets in response to plasma treatment to better understand how plasma therapy may affect the outcome disease.
In vitro studies on plasma-treated leukocytes
For detailed information on immune cell subtypes and their fate and function in health and disease, the reader is referred to comprehensive overviews (Delves et al., 2017; Weaver and Murphy, 2017) . In brief, the immune system consists of an innate and adaptive arm both of which are present in humoral (antibody-dependent) and cellular immunity. Granulocytes (predominantly neutrophils) and monocytes/macrophages are innate immune cells that form the first line of defense against microorganisms, which are recognized by evolutionary conserved molecular patterns. Granulocytes and monocytes infiltrate tissue sites from the vasculature. By contrast, tissue-resident macrophages are permanent regulators of inflammation in virtually all types of tissues. Lymphocytes recognize new antigens that aid, e.g. microbes to evade innate immune responses or characterize tumor cells as different from non-malignant cells. B lymphocytes generate antigen-specific anti bodies with the help of CD4 + T helper cells, whereas CD8 + T lymphocytes lyse sick, malignant or infected cells. This makes neutrophils, monocytes/macrophages and T lymphocytes central immune subtypes for studying responses to plasma. A summary of cytokine secretion as well as major plasma effects is given in Table 1 and Figure 1 , respectively.
Lymphocytes -fragile to reactive species
Lymphocyte essentially are in one of two states: non-activated (resting, non-stimulated) and activated (stimulated). Activation takes place upon specific binding of the T cell or B cell receptor to the target cell ligand together with proper costimulatory signals (Teixeiro and Daniels, 2010) . In T cells, this leads to a number of tyrosine phosphorylation steps that signal with the help of transmembrane and cytoplasmic adapter proteins into the mitogen-activated kinase pathway and activation of the transcription factor activator protein 1 (AP1). Utilizing mitogens such as phytohemagglutinin or phorbol-myristate-acetate to trigger these signaling complexes, lymphocyte activation can be facilitated in all cells independent of the specificity of individual T or B cell receptors. This is useful for comparative studies with lymphocytes, e.g. using physical plasma (Table 1) . Consequences of lymphocyte activation are changes in morphology, surface marker expression pattern and level, metabolic programming, proliferation and release of cytokines and chemokines (Reddy et al., 2004; Kramer et al., 2014) .
Reactive species levels fine-tune physiological responses and cell fate in lymphocytes (Kong and Chandel, 2017) . Non-activated lymphocytes readily undergo apoptosis in response to plasma-derived reactive species already at short treatment times. This was seen in a comparison of six different human cell lines (Wende et al., 2014) , of eight subpopulations of human mononuclear blood cells and of three rat spleen immune cell types (Haertel et al., 2012) . Primary lymphocytes are more sensitive compared to the Jurkat T lymphocyte cell line (Bundscherer et al., 2013a) . Lymphocytes have been 
+ / + + / + + + in the control columns indicate baseline levels; − indicates that no release is identified; = indicates no change of plasma compared to control conditions; ↑ and ↓ indicate an increase or decrease in concentration, respectively, of the plasma compared to the control group. GM-CSF, Granulocyte-macrophage colony-stimulating factor; IFNγ, interferon gamma; IL, interleukin; RANTES, regulated on activation, normal T cell expressed and secreted; TGFβ, tumor growth factor beta; TNFα, tumor necrosis factor alpha; n.d., not determined. PBMC were isolated from donor blood using Ficoll (Sigma-Aldrich, Taufkirchen, Germany) density gradient centrifugation . 1 × 10 6 PBMC/ml RPMI1640 cell culture medium (supplemented with 10% FCS, 2% glutamine, 1% penicillin/streptomycin; all Sigma-Aldrich, Taufkirchen, Germany) either were stimulated with phytohemagglutinin (PHA, 500 ng/ml; eBioscience, Frankfurt, Germany) or were left unstimulated (naïve) over night. Subsequently, cells were exposed for 60 s to an atmospheric pressure argon plasma jet (kINPen at three standard liters per minute flow gas; neoplas tools, Greifswald, Germany) or were left untreated. Suspensions were incubated for 24 h at 37°C, and supernatants were collected and stored at −20°C until analysis. For neutrophils, cells were isolated from fresh donor blood using dextran (Sigma-Aldrich, Taufkirchen, Germany) to sediment erythrocytes (Bekeschus et al., 2016a) . 1 × 10 6 cells were seeded in Hank's balanced salt solution (Biochrome, Berlin, Germany). Cell suspensions either were exposed to plasma for 180 s or left untreated. Twenty-four hours later, supernatants were harvested and stored at −20°C until analysis. Data are from several technical replicates of one to three donors and modified from Bekeschus (2014) . ascribed a low removal rate of oxidants from the extracellular environment . Plasma-induced lymphocyte apoptosis is not different to intrinsic apoptotic pathways as previously described (Tripathi and Hildeman, 2004) , including mitochondrial membrane depolarization, caspase 3 activation and phosphatidylserine exposure . Potassium efflux was also reported after plasma treatment (Shi et al., 2008) . In a lymphocyte cell line, exposure to plasma promoted growth arrest (Bundscherer et al., 2015) . Lymphocyte cell death is clearly attributed to plasma-reactive species that oxidize the cell's membrane and in secondary reactions the cytosol and mitochondria . Interestingly, mitogen-activated lymphocytes withstand plasma-induced apoptosis to a much greater extent compared to non-activated cells at the same treatment time and amount of cells (Bekeschus et al., 2013c) . This implies that the oxidative cell death is controlled by intracellular thiol switches translating the oxidative challenge into a specific response (Hanschmann et al., 2013) . Indeed, T lymphocytes surviving the plasma treatment upregulated intracellular glutathione levels in response to stimulus . Oxidation in lymphocytes is associated with STAT6 activation and TH2 polarization . T cell receptor-dependent activation of lymphocytes triggers endogenous generation of hydrogen peroxide that inhibits the MEK-ERK pathway (Kwon et al., 2003) . At the same time, plasma treatment triggers proapoptotic p38/JNK signaling . Among lymphocytes, there are numerous subtypes, each with specific effector functions. Detailed analysis on apoptosis in CD4 + T cells revealed a prominent demise of memory over naïve T cells, favoring the survival of terminally differentiated CD62L − cells (Bekeschus et al., 2016a ). This corroborates findings on metabolic profiling of memory T cells (Franchina et al., 2018) and T cell studies using hydrogen peroxide (Lichtenfels et al., 2012) . Terminally differentiated T cells poorly proliferate, although proliferation is a hallmark of T cell activation.
T cell proliferation is key in battling disease, as it needs the right amount of the right clone at the right time and the right place to carry out the effector functions needed. Mitogen-activated T cells exposed to physical plasma either continue proliferation or die . They do not undergo senescence, i.e. survive but stop proliferation. This is important because an immune response -once triggered -needs to be sustained to combat environmental threats. Vice versa, plasma treatment does not induce NF-κB activation (Bekeschus et al., 2016b) and proliferation (Bekeschus et al., 2013c) in non-activated T cells per se. This is crucial, because antigen-independent replication of T cells would be a major threat for autoimmune reactions (Wing and Sakaguchi, 2010) . Nonetheless, exposure of T cells to plasma induces changes in the their surface marker profile (Bekeschus et al., 2016c) . This supports finding that reactive species act as signaling molecules in lymphocytes (Reth, 2002) and are required for activation following, e.g. T cell receptor stimulation (Sena et al., 2013) . Such simulation is usually followed by the release of inflammatory mediators such as cytokines and chemokines. In resting peripheral blood mononuclear cells (PBMC), consisting of monocytes and lymphocytes, a noteworthy modulation in lymphocyte-secreted cytokine release was not observed after plasma treatment (Table 1 , unpublished results) (Bekeschus, 2014) . Upon mitogen stimulation of lymphocytes, exposure to plasma decreased the release of more than half of the targets investigated. This includes interleukin (IL) 17, a potent inflammatory cytokine of T H 17 cells (Korn et al., 2009) , and granulocyte-macrophage colony-stimulating factor that drives autoinflamation (Codarri et al., 2011) . However, as plasma treatment drives many lymphocytes in apoptosis, it is difficult to decipher whether there is a decreased release due to cell death or due to an active down-regulation. On the transcriptomic level, plasma increased the activity of AP1 family members such as JUND and FOSB in a lymphocyte cell line . This led to a concomitant transcriptional decrease in IL-13 and IL-23 receptor as well as IL-1β expression levels.
In summary, lymphocytes are not 'immune' but readily undergo a subtype-specific degree of apoptosis in response to physical plasma treatment. At the same time, they react to plasma exposure to some extent as for instance they redox-regulate their cytokine or surface marker profile as well as antioxidant defense.
Monocytes/macrophages -robust regulators
Among PBMC, monocytes is the most robust subset in response to plasma treatment . Similar findings were concluded in human monocytederived macrophages (Volotskova et al., 2016) . Dying cells, however, follow the course of intrinsic apoptotic pathways including loss of mitochondrial membrane potential and caspase activation (Kaushik et al., 2014) . The low sensitivity to oxidant-induced cell death seems appropriate in the light of monocytes/macrophages killing engulfed bacteria via the intraphagosomal release of reactive oxygen and nitrogen species (Forman and Torres, 2002) . Mitogen activation of lymphocytes in PBMC and their concomitant cytokine release and activation-marker-profile neither increases nor decreases this low cytotoxic response. This suggests that this cells' sensitivity to oxidant-induced cell death is relatively unaffected by the inflammatory microenvironment. The human monocyte cell line THP-1 is even 10 times more robust to plasma treatment compared to primary monocytes (Bundscherer et al., 2013a) . This is consistent with the finding that some types of acute myeloid leukemia cells are not only potent producers of reactive species themselves but also display defective apoptotic signaling via the p38-MAPK pathway that is usually associated with ROS-induced damage (Hole et al., 2013) . Such ROS accumulation is seen in the consistent increase in intracellular oxidation in response to plasma treatment despite lack of apoptotic cell death (Bekeschus et al., 2016a) . Eventually, this also leads to a decrease in glucose metabolism as well as ATP and lactate production (Kaushik et al., 2015) resulting in slower cell cycle progression.
Although plasma is poorly toxic in human monocytes/ macrophages, the exposure to reactive species is actively received and translated inside the cells. Comparing the proteome of PBMC/THP-1 derived microparticles, plasma treatment induced an upregulation of redox-related enzymes including heat shock protein 90, peroxiredoxins 6 and superoxide dismutase . In THP-1 monocytes, plasma treatment redox-regulates significant changes in, for example, intracellular glutathione, mitochondrial mass, IL-8 release, cell size, and proteins of the Nrf2 antioxidant phase II and the YinYang1 pathway including HMOX1 Bekeschus et al., 2016b; Schmidt et al., 2016) . These findings suggest both plasma-induced differentiation and adaptation. The importance of ROS in driving macrophage differentiation has been well documented (Covarrubias et al., 2013) . Plasma-mediated adaptation in handling reactive species within monocytes is an important defense mechanism of their survival, as these cells frequently enter, for instance, oxidative or hypoxic tumor sites (Lewis and Murdoch, 2005) . Co-culture studies of cancer cells with macrophages found an increase in macrophage-derived tumor necrosis factor (TNF) α and a concomitant decline in tumor cell growth (Kaushik et al., 2016 ). An important feature of macrophages is migration into cancers but also into wounds after injury. Here, immigrating monocytes differentiate into macrophages (Brancato and Albina, 2011) . Plasma treatment was shown to spur the migratory potential of RAW264.7 macrophages (Miller et al., 2014) .
In summary, monocytes/macrophages are highly robust ('immune') against plasma-derived oxidant cell death. These cells clearly respond and react to ROS/RNS from plasmas by redox signaling pathways to modulate their inflammatory and migratory potential as well as cellular phenotype.
Neutrophils -toxic suicide
Their main role is to quickly infiltrate tissue upon injury (Dovi et al., 2004) , and to remove pathogens (Amulic et al., 2012) . Tissue immigration is known to be potentially reversible (Holmes et al., 2012 ) mediated via redox signaling mechanisms, including NO (Suschek and Opländer, 2016) and hydrogen peroxide (Yoo et al., 2011) . Overall, neutrophils are ascribed a detrimental role in pathological wound healing (Brubaker et al., 2011 (Brubaker et al., , 2013 McDaniel et al., 2013) and cancer (Demers and Wagner, 2013; Andzinski et al., 2015; Tuting and de Visser, 2016) although some reports suggest the opposite (Nishio et al., 2008; Yan et al., 2014; Sionov et al., 2015) . Neutrophils have a short half-life of 6-12 h in vivo (Rankin, 2010) and in vitro (Fadeel et al., 1998) . They possess some extraordinary features: a potent and fast oxidative burst (Winterbourn and Kettle, 2013), extracellular trap formation (Brinkmann et al., 2004) , and -a recent field of research -active regulation of adaptive immunity (Kumar and Sharma, 2010; Mantovani et al., 2011; Scapini and Cassatella, 2014) . Plasma exposure of neutrophils induces little apoptosis, leads to small but significant reduction of NADPH oxidase activity, induces a strong release of IL-8, leaves microbial killing unaltered and mediates a robust release of neutrophil extracellular traps (NETs) (Bekeschus et al., 2016c) . NETs are thought to be of poor prognosis in diabetic wounds (Wong et al., 2015) and supposed to support cancer progression (Cools-Lartigue et al., 2013) . However, senescent (inactive but viable) neutrophils are one of the prime features of chronic wounds (Ward et al., 2011) , and their removal via NET formation of apoptosis may be one way for wound resolution.
Neutrophil function is also regulated by plasma treatment. Proteomic analysis of neutrophil-derived microparticles showed extensive modulation upon exposure to plasma . This included antimicrobial as well as redox regulating proteins such as annexins, heat shock proteins, myeloperoxidase, lactotransferrin, collagenase, elastase, peroxiredoxins, superoxide dismutases and thioredoxin. Interestingly, these targets were also identified to be crucial in the course of acute wound healing (Bekeschus et al., 2018a) . With regard to cytokine secretion, we observed a decrease in IL-1β, IL-6 and TNFα (Bekeschus, 2014) in response to plasma treatment (Table 1) , suggesting a decrease in inflammation with regard to these mediators.
In summary, neutrophils are very sensitive (NET formation) and reactive (inflammatory modulation) to exposure to cold physical plasma. Despite numerous in vitro findings of plasma-treated leukocytes, disease models in animals or patient material are more accurate to decipher the relevance of immune cells upon plasma treatment under different conditions.
Leukocytes and in vivo plasma therapy Wound healing
Wound healing is controlled by the regulation of inflammation, which is governed in large parts by leukocytes (Baum and Arpey, 2005; Broughton et al., 2006; Raffetto, 2013) . For a detailed overview of the exact roles of each leukocyte population as well as their kinetics in the different phases of wound healing, the reader is referred to comprehensive reviews on these topics (Li et al., 2007; Kim et al., 2008; Havran and Jameson, 2010; Koh and DiPietro, 2011) . A large number of studies has provided clear evidence for plasma therapy for the acceleration of healing responses in vivo (Arndt et al., 2013; GarciaAlcantara et al., 2013; Jacofsky et al., 2014; Nasruddin et al., 2014; Ngo Thi et al., 2014; Arndt et al., 2015; Nasruddin et al., 2015; Xu et al., 2015; Fathollah et al., 2016; Lee et al., 2016; Shao et al., 2016; Choi et al., 2017; Kubinova et al., 2017; Naderi and Zaefizadeh, 2017; Schmidt et al., 2017a; Chatraie et al., 2018; Pekshev et al., 2018) . Currently, there is no accepted chronic wound model in mice or rats, which is why experimental healing response in acute wounds under plasma therapy were mainly investigated. Kubinova and colleagues could not observe any differences in inflammatory reactions, macrophage infiltration, or macrophage polarization between control and plasma treated acute rat wounds (Kubinova et al., 2017) . In mice, inflammatory infiltrates were shown to occur on day 7 in dependence of plasma treatment time (Xu et al., 2015) . Specifically, the group of Sigrid Karrer reported an increase of macrophages as well as neutrophils in the early phase of wound healing on day 5 (Arndt et al., 2013) . This was concomitant with increased levels of MCP-1 and IL-6 but not TGFβ, which suggests sustained inflammation and continuous monocyte attraction (Deshmane et al., 2009) . Another study identified similar TGFβ levels as well but also found only similar numbers of macrophages and neutrophils on day 3 and non-significantly fewer numbers on day 7. The authors concluded a plasma-induced acceleration of the late but not early phase of inflammation (Nasruddin et al., 2014) . A similar observation was made in a recent report in non-infected wounds (Chatraie et al., 2018) . In acute infected wounds, plasma was found to change neutrophil influx in the acute phase of inflammation but not in chronically infected, later wounds stages (up to day 35) (Yu et al., 2011) . In the late stages of physiological wound healing, leukocytes retract from tissue (Agaiby and Dyson, 1999) . Through plasma-assisted accelerated wound closure, complete re-epithelialization occurred whereas control wounds still presented neutrophil and T cells infiltrates . A study in rats underlined this finding in non-infected as well as infected wounds (Shekhter et al., 2005) . In skin biopsies of plasma-treated patients wounds, a decrease of macrophages with increased phagocytic activity during sustained healing was presented (Pekshev et al., 2018) . With a plasma source generating vast amounts of NO, tens of thousands of patients have been treated so far (Shekhter et al., 2005) . NO-based wound healing was accompanied by an early increase and later on decrease in inflammation concomitant with an activation of macrophages. The authors speculate on an interesting NO-derived chemistry in the wound bed, involving in situ generation of, e.g. peroxynitrite. This addresses one of the major questions in the field of plasma medicine, namely which plasmaderived reactive species drive the responses observed. Clearly, redox chemistry and signaling is an integral part in translating the cellular perception of effects mediated by oxidation (Sen and Roy, 2008) . For instance, redox regulation of plasma treatment in wound healing has been documented by an increase in catalase and glutathione reductase and a decrease in superoxide dismutase levels in wounds (Salehi et al., 2015) . However, persistent oxidation can lead to auto-immunity that is often T cell driven (Israeli et al., 2009; Perricone et al., 2009; Peters et al., 2009) . Using an Organization for Economic Cooperation and Development (OECD) accredited assay for T cell driven skin sensitization, van der Linde and colleagues could not observe adverse effects after repeated exposure to plasma in a standardized murine model (van der Linde et al., 2017) . Long-term studies on plasma treatment are also important. Follow-up studies performed 1 year after wounding in mice or patients did not show any differences between plasma and control groups (Metelmann et al., 2013; Schmidt et al., 2017b) , suggesting plasma changes only the course of wound healing (and presumably leukocyte dynamics) but not its outcome. However, direct functional consequences of dynamic changes in leukocyte infiltrates are still poorly elucidated. For this, interventional studies are needed that modulate immune cell activity and redox processes in plasma therapy to establish a link between redox signaling, leukocyte function and healing responses.
In summary, many studies observed a role of tissue inflammation and leukocyte dynamics, clearly ascribing, especially phagocytes, a role to react to plasma treatment of tissue and/or its subsequent responses. Yet, a multitude of different plasma devices, animal models and readout systems are used. This hinders clear conclusions to be drawn on specific types of reactive species, leukocyte phenotypes, or immune cell infiltrates that are needed for beneficial, plasma-driven wound healing responses.
Cancer
Undoubtedly, there is a need to for new avenues in cancer therapy. Plasma treatment seems a promising approach for killing tumor cells, as has been recently reviewed (Babington et al., 2015; Kajiyama et al., 2017; Yan et al., 2017) . A large body of studies using different kinds of animal cancer models underline this notion (Keidar et al., 2011; Vandamme et al., 2011a Vandamme et al., ,b, 2012 Brulle et al., 2012; Daeschlein et al., 2013; Utsumi et al., 2013; Walk et al., 2013; Kang et al., 2014; Chernets et al., 2015; Hattori et al., 2015; Ikeda et al., 2015; Mashayekh et al., 2015; Mirpour et al., 2016; Tanaka et al., 2016; Chen et al., 2017; Liedtke et al., 2017; Nakamura et al., 2017; Takeda et al., 2017) , and first patients benefited from plasma therapy (Metelmann et al., 2018) . However, the research field is young, and most effects observed are attributed directly to plasma effects rather than the secondary effects of immune cells. Thus, studies on immune infiltrates in plasma-treated experimental tumor models are scarce. By unleashing the power of adaptive immunity, antibodybased immunotherapies have been the major breakthrough in oncology in the 21st century so far (Sullivan, 2017) . The concept is based on the idea that dying tumor cells release damage-associated molecular patterns, which can aid in eliciting immunogenic cell death and tumor-specific T cells (Garg et al., 2015; Galluzzi et al., 2017; Showalter et al., 2017) . However, tumor-specific T cells are inhibited by immunosuppressive molecules such as CTLA-4 or PD1, which are the targets for checkpoint inhibitors (Pardoll, 2012) . The first evidence of the importance of T cells in anticancer effects of plasma was recently reported by Mizuno and colleagues (Mizuno et al., , 2018 , although more direct studies need to be carried out (Bekeschus et al., 2018b) . Similar to the development of other physical therapies for cancer treatment such as ionizing radiation (Adkins et al., 2014) , Electrochemotherapy (Calvet et al., 2014) , and photodynamic therapy (Panzarini et al., 2013) ground-breaking findings in the field of immuno-oncology are likely spur future research in plasma medicine for investigating tumor immunity in more detail.
Conclusion
It is widely accepted that the immune system is a key contributor in physiological and pathological processes. Experimental application of cold physical plasma in translational, medical and veterinary science therefore will increasingly focus on immune cells as mediators of effects. Most conclusive evidence about the role of leukocyte populations in plasma medicine will be generated either using genetic mouse models (negative for a distinct immune cell type) or antibody-mediated immune cell depletion. While the field of plasma medicine is waiting for such studies, adjacent fields of dermatology and oncology give a promising forecast of exciting results to come in immunological sciences.
